Complete Omics

What Complete Omics does

Complete Omics is a clinical multi-omics diagnostics company founded in 2019 by Dr. Qing Wang in Baltimore, Maryland, operating a CLIA-certified, CAP-accredited clinical laboratory that translates ultra-deep proteomics and multi-omics measurements into regulated diagnostic tests and research services. Its core technology centers on two patented platforms: Complete360®, an ultra-deep clinical proteomics platform that quantifies approximately 10,000 proteins per patient sample with clinical-grade reproducibility, and Valid-NEO®, a targeted proteomics platform for direct, ultra-sensitive detection and absolute quantification of tumor neoantigens from small biopsy specimens. Supporting platforms include DEEPER-Seq for damaged-sample genomics, SAFE-SRM and MANA-SRM for multiplexed targeted proteomics, Neo-True for neoantigen validation, and MetaBoost for metabolomics.

The company monetizes through four channels: CPT-coded, insurance-reimbursable clinical testing across oncology, cardiovascular (via the Prevencio HART partnership), neurology, and immunology; fee-for-service research programs for pharmaceutical, biotechnology, and academic customers; sale of Target™ research kits through an online storefront; and platform licensing for companion diagnostics and therapeutic co-development. Go-to-market is sales-led and enterprise-direct, with a substantial portfolio of academic and biopharma collaborations spanning Johns Hopkins, Stanford, MD Anderson, MSKCC, Bayer, Arvinas, Generate Biomedicines, and Grünenthal, supported by 40+ global patents and 20+ Cell/Nature/Science publications that establish scientific credibility.

Name

Complete Omics

Legal name

Complete Omics Inc.

Website

https://completeomics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Complete Omics is a CLIA-certified, CAP-accredited clinical multi-omics company that operates Complete360® ultra-deep proteomics and Valid-NEO® neoantigen platforms to deliver CPT-coded diagnostic tests and research services to healthcare providers, biopharma, and academic institutions.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Proteomics & Mass Spectrometry Services (HLAGANAB), Proteomics & Biomarker Analytical Testing (HLAGADAG), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Clinical proteomics services
• Multi-omics diagnostics
• Neoantigen detection
• Precision medicine diagnostics
• Companion diagnostics

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Testing Services: CLIA-certified, CAP-accredited clinical laboratory offering multi-omics diagnostic tests across oncology, cardiovascular, neurology, and immunology. Services are CPT-coded and insurance-reimbursable, providing clinical-grade molecular diagnostics directly to healthcare providers and patients.
2. Research Services: Comprehensive research services providing high-quality, top-journal-grade multi-omics data for pharmaceutical companies, biotech firms, and academic institutions. Six service programs covering proteomics, genomics, metabolomics, and single-cell omics.
3. Target™ Kits: Sale of proprietary research kits for sample analysis, enabling external researchers to utilize company technologies.
4. Platform Licensing: Technology platforms including Complete360 and Valid-NEO available for licensing to pharmaceutical partners and healthcare organizations for companion diagnostics and therapeutic development.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

Complete Omics delivers ultra-deep clinical proteomics and multi-omics diagnostic services through its CLIA-certified, CAP-accredited laboratory. The company's two proprietary platforms, Complete360® (quantifying thousands of proteins per sample for disease screening and biomarker discovery) and Valid-NEO® (direct neoantigen detection for precision oncology companion diagnostics), form the foundation of clinical testing services across oncology, cardiovascular, neurology, and immunology, supplemented by research services and Target™ Kits.

Product overview

Complete Omics is a platform company offering integrated multi-omics diagnostic services centered on two patented platforms: Complete360® for ultra-deep clinical proteomics enabling thousands-of-protein quantification per sample, and Valid-NEO® for neoantigen discovery and clinical companion diagnostics. The company provides research and clinical services across oncology, cardiovascular, neurology, and immunology through its CLIA-certified, CAP-accredited laboratory, complemented by the CompleteCohort® large cohort service, DEEPER-Seq® genomics platform, and Target™ Kits product line.

Differentiator

Problem solved

Functional benefit

Brands

• Complete360: Ultra-deep clinical proteomics platform capable of measuring thousands of proteins across complex clinical samples for disease screening and diagnostics
• Valid-NEO
• CompleteCohort
• DEEPER-Seq
• SAFE-SRM
• MANA-SRM
• Neo-True
• MetaBoost

Products and services

• Complete360® Ultra-deep clinical proteomics platform enabling large-scale, high-sensitivity protein quantification from plasma and tissue samples. Quantifies thousands of proteins per patient sample with clinical-grade reproducibility for early disease detection, therapeutic monitoring, and population-scale biomarker discovery. Measures approximately 10,000 proteins per patient sample and 4,550 proteins in plasma.
• Valid-NEO® Multi-omics platform for neoantigen discovery and validation, supporting companion diagnostics for precision oncology. Enables direct detection and absolute quantification of patient-specific neoantigens from limited biopsy samples for mutation-directed immunotherapy, including mRNA vaccines, therapeutic peptides, engineered cell therapies, and bispecific antibodies.
• CompleteCohort® Large cohort multi-omics service enabling population-scale proteomic profiling for biomarker discovery and clinical validation studies across diverse patient populations.
• DEEPER-Seq® Patented barcoded single-strand library plus dual-RNA probe capture approach for genomics. World's only dual-RNA probe-based targeted NGS pipeline for damaged samples including FFPE, plasma, fossil, and ancient samples.
• Target™ Kits Proprietary research and clinical kits for sample preparation and analysis workflows, enabling external researchers to utilize Complete Omics' targeted proteomics technologies.
• Oncology Services Clinical diagnostic services covering multi-cancer screening, druggable target assessment, multiple myeloma monitoring, prostate cancer risk assessment beyond PSA, and personalized cancer therapeutics, integrating proteomic, metabolic, and molecular architectures for multi-dimensional cancer panels.
• Cardiovascular Services AI-driven cardiovascular risk assessment services using Prevencio's HART platform integrated with Complete360. Includes HART CADhs™ (CPT 0308U), HART CVE™ (CPT 0309U), and HART PAD™ panels for MACE risk quantification and coronary artery disease detection, achieving AUC ≈ 0.85 versus AUC ≈ 0.52 for standard-of-care cardiac stress testing.
• Neurology Services Neurodegenerative disease screening and prediction services with actionable druggable strategy recommendations. Ultra-sensitive molecular detection engineered for early-stage signals in Alzheimer's disease and Parkinson's disease, enabling detection years before symptoms become obvious.
• Immunology Services Immune network and cytokine signature profiling services including pro-inflammatory cytokines, anti-inflammatory mediators, chemokines, and growth factors. Multiplexed quantification of immune signaling proteins enabling systems-level immune status characterization for autoimmune disease diagnostics, infectious disease testing, cytokine storm detection, and immunotherapy response monitoring.
• Neoantigen and Cancer Immunotherapy Services Personalized cancer neoantigen detection services for mRNA vaccines, therapeutic peptides, engineered cell therapies, and bispecific antibodies. Includes HERV-derived neoantigen identification for shared antigen strategies, supporting immunotherapy development and validation.

Quantifiable outcome

• ~10,000 proteins quantified per patient sample in clinical setting
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

30 partnerships are on record, tiered core and minor.

• M20 GenomicscoreStrategic or Co-development Partner · 1 August 2024Strategic partnership to advance single-cell multi-omics for disease research and precision medicine. The partnership includes establishing a joint laboratory in Baltimore, Maryland to accelerate development and deployment of single-cell multi-omics technologies.
• PrevenciocoreStrategic or Co-development PartnerCollaboration on AI-driven multi-protein cardiovascular diagnostics. Prevencio's HART platform integrates validated multi-analyte protein signatures with advanced machine-learning algorithms, deployed within Complete360 infrastructure for cardiovascular risk assessment.
• Dr. Bert Vogelstein / Johns Hopkins UniversitycoreStrategic or Co-development PartnerLong-term collaboration providing cutting-edge multi-omics molecular diagnostics services. Dr. Vogelstein's group works with Complete Omics on identifying novel personalized cancer therapeutic targets and cancer protein biomarkers.
• Columbia UniversityminorStrategic or Co-development PartnerCollaboration with Professor Kam W. Leong's team from Columbia University on clinical proteomics project leveraging Complete360 quantitative proteomics assays for clinical discoveries.
• Tel Aviv UniversityminorStrategic or Co-development PartnerCollaboration with Professor Miguel Weil's team on clinical proteomics project focusing on Complete360 body fluid proteomics assays for clinical discoveries.
• MD Anderson Cancer CenterminorStrategic or Co-development PartnerCollaboration on variety of molecular diagnostics projects combining clinical expertise with Complete Omics' multi-omics platforms.
• Memorial Sloan Kettering Cancer Center (MSKCC)minorStrategic or Co-development PartnerCollaboration with world leader in cancer care on variety of molecular diagnostics projects.
• Arvinas PharmaceuticalsminorStrategic or Co-development PartnerCollaboration with pharmaceutical company inventing proprietary PROTAC protein degraders on clinical proteomics projects.
• Generate BiomedicinesminorStrategic or Co-development PartnerCollaboration on series of immunopeptidomics projects supporting protein-targeted drug generation platform.
• GrünenthalminorStrategic or Co-development PartnerCollaboration with pharmaceutical company headquartered in Aachen, Germany on clinical single-cell based proteomics projects.
• Baylor College of MedicineminorStrategic or Co-development PartnerCollaboration with Professor Andras Attila Heczey's team on clinical proteomics projects leveraging Complete360 body fluid proteomics assays.
• Washington University in St. LouisminorStrategic or Co-development PartnerCollaboration with Professor Marco Sardiello's team using Complete360 platform for identifying novel biological mechanisms.
• Yale UniversityminorStrategic or Co-development PartnerCollaboration with Professor Dianqing (Dan) Wu on series of quantitative proteomics focusing on clinical quantitative proteomics assays for biological discoveries.
• University of PittsburghminorStrategic or Co-development PartnerCollaboration with Professor Patrick S. Moore's team on clinical proteomics projects focusing on neoantigen quantification assays for biological discoveries.
• Duke UniversityminorStrategic or Co-development PartnerCollaboration with Dr. Yiping He on grants focusing on labeling-dependent large scale quantitative proteomics assays for biological discoveries.
• Emory UniversityminorStrategic or Co-development PartnerCollaboration with Dr. Sun Shi-yong's lab in Winship Cancer Institute on clinical proteomics projects.
• University of North CarolinaminorStrategic or Co-development PartnerCollaboration with Dr. Benjamin Vincent on neoantigen-related projects.
• Rutgers Cancer Institute of New JerseyminorStrategic or Co-development PartnerCollaboration with Dr. Christian S. Hinrichs on clinical proteomics projects.
• University of Utah Huntsman Cancer InstituteminorStrategic or Co-development PartnerCollaboration with Professor Sumati Gupta's team on Complete360 proteomics assays for clinical discoveries.
• Lisbon School of MedicineminorStrategic or Co-development PartnerCollaboration with Dr. Luis Marques da Costa's team on Complete360 body fluid proteomics assays for clinical discoveries.
• Case Western Reserve UniversityminorStrategic or Co-development PartnerCollaboration with Professor Zhenghe Wang's team on clinical proteomics projects focusing on Complete360 targeted detection pipeline for biological discoveries.
• McMaster UniversityminorStrategic or Co-development PartnerCollaboration with Dr. Yonghong Wan's lab on immunotherapies and neoantigen presentation regulation studies.
• Taipei Medical UniversityminorStrategic or Co-development PartnerCollaboration with Professor Ching-shuen Wang on RNA-seq projects using DEEPER-SeqS clinical genomics assays from hard-to-sequence clinical samples.
• Netherlands Cancer InstituteminorStrategic or Co-development PartnerCollaboration on series of quantitative phosphoproteomics projects.
• Ludwig Cancer ResearchminorStrategic or Co-development PartnerCollaboration on series of clinical proteomics projects with Ludwig Cancer Research Center.
• Frame Cancer TherapeuticsminorStrategic or Co-development PartnerCollaboration with Amsterdam pharmaceutical company on clinical proteomics projects.
• ErVaccine TechnologiesminorStrategic or Co-development PartnerCollaboration with pharmaceutical company headquartered in Lyon, France on neoantigen validation and quantification project.
• University Medical Center FreiburgminorStrategic or Co-development PartnerCollaboration with Prof. Dr. Roland Schüle from University Medical Center Freiburg on clinical proteomics projects.
• University of MinnesotaminorStrategic or Co-development PartnerCollaboration with Dr. Rebecca Morris on single cell omics analysis projects.
• University of Maryland, Baltimore County (UMBC)minorStrategic or Co-development PartnerCollaboration for training intern students and supporting career development in multi-omics diagnostics.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Quanterix: Quanterix commercializes ultra-sensitive Simoa immunoassay technology for protein biomarker detection at sub-pg/mL levels. It overlaps with Complete Omics in high-sensitivity protein quantification and serves similar pharma and academic proteomics customers.
• Olink: Olink provides protein biomarker discovery platforms based on proximity extension assay (PEA) technology, serving pharma, biotech, and academic customers with high-throughput proteomics. It is a direct competitor to Complete Omics' Complete360 platform in clinical proteomics research services and biomarker discovery.
• SomaLogic (Standard BioTools): SomaLogic operates the SomaScan platform for large-scale proteomic biomarker measurement using modified aptamers, with deep pharma and academic adoption. Now part of Standard BioTools, it directly competes with Complete Omics in protein biomarker discovery and clinical proteomics services.
• Seer: Seer has developed the Proteograph product suite for deep, unbiased plasma proteomics at scale. It targets the same proteomics research-services and clinical-discovery customer base as Complete Omics' Complete360 platform.
• Prevencio: Prevencio develops AI-driven multi-protein cardiovascular diagnostics (HART platform) and is a current strategic partner of Complete Omics. Its HART algorithm is integrated into Complete360, making it both a partner and a closely adjacent AI-proteomics diagnostic peer.

Emerging players

• Nautilus Biotechnology: Nautilus is developing a single-molecule protein analysis platform aimed at deep proteome coverage across broad dynamic range. It targets overlapping deep-proteomics applications but is pre-commercial relative to Complete Omics' already-deployed CLIA platform.

Broad incumbents

• Standard BioTools: Standard BioTools (formerly Fluidigm) offers mass cytometry and now proteomics platforms including the SomaScan acquisition. It is a broader incumbent in life-science instrumentation and proteomics with overlapping customer segments to Complete Omics.
• Thermo Fisher Scientific: Thermo Fisher provides mass spectrometry instruments, workflows, and proteomics services used by similar pharma and academic customers. As a broader instrumentation and CRO incumbent, it competes for proteomics services wallet share and licenses in adjacent workflows.
• Bio-Techne (ProteinSimple): Bio-Techne offers protein analysis reagents, ELISA, and ProteinSimple-branded capillary Western and immunoassay platforms. It is a broad incumbent in protein research tools with overlapping customer segments in clinical and translational proteomics.
• Bruker: Bruker manufactures high-resolution mass spectrometers and proteomics workflows (timsTOF, Astral) widely used in clinical and translational proteomics. As an instrumentation incumbent, it competes for instrumented proteomics service work and supplies overlapping customer labs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/completeomics
• Facebookfacebook.com/completeomicsinc
• LinkedInlinkedin.com/company/complete-omics-inc
• Instagraminstagram.com/completeomics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Complete Omics